TargetBeta
HRH1
histamine receptor H1 · Histamine receptors
4 programs in company-led studies act on HRH1, from 4 companies: 0 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Diphenhydraminerule | Johnson & Johnson | phase 4 | 161 running | – | ChEMBL |
| desloratadinerule | Organon | phase 4 | 400 running | – | ChEMBL |
| fexofenadinerule | Sanofi | phase 4 | 380 running | – | ChEMBL |
| bilastinerule | Faes Farma | phase 4 | 190 running | – | ChEMBL |
Conditions their studies are in
- Rhinitis, Allergic, 3 programs
- Rhinitis, Allergic, Seasonal, 3 programs
- Urticaria, 3 programs
- Asthma, 2 programs
- Chronic Urticaria, 1 program
- Conjunctivitis, Allergic, 1 program
- Depressive Disorder, Major, 1 program
- Hypersensitivity, 1 program
- Multiple Sclerosis, 1 program
- Nasal Obstruction, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.